Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review To the Editor: Type I, adult-onset pityriasis rubra pilaris (PRP) is a papulosquamous disorder sometimes resistant to treatment with acitretin or methotrexate. For refractory PRP, tumor necrosis factor (TNF) inhibitors, ustekinumab, and secukinumab have been reported to be useful. 1, 2 Because evidence of successful treatment of PRP with biologics is described in case reports and case series, preferential reporting of outcomes is possible. 3 Marked improvement of disease has been demonstrated in most cases involving biologics, but we had a different experience at our institution, as described in previous studies. 3, 4 Furthermore, a recent survey-based case series noted that only 4 out of 10 patients with an unquestionable diagnosis of PRP treated with TNF-inhibitors reported them as helpful. 5 To clarify these inconsistencies, we aimed to delineate the various outcomes possible upon treatment with a biologic, such that a dermatologist treating PRP with biologics can judge the clinical course of his or her patients against those described in the literature. We conducted a review of the literature to characterize cases that improved markedly ([75% reduction in body surface area involved) or partially (\75% reduction), cases in which PRP relapse was described, and cases that did not improve with biologic treatment. Our PubMed query was current as of October 30, 2017, with search and inclusion criteria described in A total of 35 articles describing 54 cases of type I PRP satisfied our search/inclusion criteria, and 50 cases were supported with histologic evidence. Overall, we identified 40 instances in which PRP response to biologics was marked (37) or partial (3), and no disease relapse was noted. In these 40 patients, the median length of therapy was 21 weeks, and 60% (24/40) of these patients demonstrated complete clearance of disease while on their respective biologic regimen. We identified a median time to primary response of 4 weeks, with [90% (37/40) of cases noting primary improvement at or before week 8 of their biologic regimen (Table I) .
We identified 14 cases in which either no response to a biologic was observed or improvement was followed by relapse (median week of relapse, week 14). In most cases, reports described patients improving on an alternative regimen. Only 1 patient completely failed 2 different classes of biologics.
Scarcity of data regarding unsuccessful treatment of PRP with biologics complicated attempts to identify pretreatment characteristics associated with failing a biologic. Given the absence of randomized controlled data, we could not make meaningful comparisons between different biologics. The data for this study depended on cases that were likely published because of positive treatment outcomes, creating a source of bias. However, understanding that the majority of patients reported to improve on a biologic showed primary response at or before week 8 is helpful. Of the 8 biologic regimens identified in this review that showed no clinical response, the duration of treatment for 5 of these were 12 weeks or longer. Ultimately, biologics appear to be a sometimes-useful resource for treating refractory To the Editor: Given that most malignant melanomas (MMs) are found by patients or their partners, 1 it is critical to provide the public with accurate and accessible education on MMs. Knowledge of early features of MM might reduce delay in seeking medical attention. 2 Current MM education involves passive information transfer through print materials and noninteractive websites. In this pilot study, we evaluated the effectiveness of an online, publicly accessible educational intervention that uses a game-based learning (GBL) approach to teach the features of MM.
Tapamole (bit.ly/tapamole) was developed by a multidisciplinary team from Mayo Clinic. All MM images were retrieved from a Mayo Clinic image database and had confirmed MM pathology. Benign nevi images were selected on the basis of clinical and dermoscopic appearanceThe study was approved by the Institutional Review Board of the Mayo Clinic (17-000937). Participants were voluntarily recruited from social media websites (Facebook, LinkedIn) to partake in the study. After completing a survey on background information, participants were randomized 1:1 to either intervention or no intervention, followed by a recognition test. The intervention group played Tapamole, which shows examples of the ABCDEs (assymmetry, border, color, diameter, evolution) of MM using 25 MM and 60 benign nevi images. The game uses pattern recognition to teach the features of MM and is typically completed in \5 minutes. The nonintervention group proceeded directly to the recognition test. The recognition test showed 9 images of either MM or benign nevi, and the user was asked to categorize the image as an MM or not an MM without any feedback. Clustered binary data equations in Zhou 3 generalized estimating equation model with log link were used to test the sensitivity, specificity, and accuracy between groups. Paired t test was used to compare preintervention and postintervention confidence scores.
During March 10-15, 2017, a total of 106 participants completed the online survey; 50 were randomized to the intervention group. The median age range of the participants was 21-30 years, 68% were college graduates, and 2% had a history of melanoma. Participants randomized to the intervention group had significantly superior sensitivity (95% vs 72%, P \.0001) and accuracy (70% vs 60%, P ¼ .011) but similar specificity (58% vs 55%, P ¼ .46) for recognizing MM (Table I) . Ninety-two participants (87%) preferred an online health education game over printed health education pamphlets. Self-rated confidence for MM recognition increased from an average of 2.5 to 3.8 out of 5 (P \.0001) after playing Tapamole. Eighty percent of participants indicated that they would recommend the game to a friend or family member.
Previous MM patient education studies relied on printed pamphlets for content delivery, which is not optimal given the increasing consumption of web-based medical information. 4 In this study, we report that an online GBL intervention, Tapamole, is effective at improving MM recognition and is preferred over written education by patients.
